This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Prostate Cancer
Recent Abstracts
Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: Active surveillance and focal targeted therapy - Abstract
May 4, 2011
Results of vardenafil mediated power Doppler ultrasound, contrast enhanced ultrasound and systematic random biopsies to detect prostate cancer - Abstract
May 4, 2011
EAU 2011 - The PCA3 score accurately predicts tumor volume and might help in selecting prostate cancer patients for active surveillance - Session Highlights
May 4, 2011
EAU 2011 - Interest of early confirmatory biopsies and centralized pathological review to select prostate cancer patients for active surveillance - Session Highlights
May 4, 2011
EAU 2011 - Non-invasive diagnosis of prostate cancer from body fluids using a panel of tumor suppressor genes - Session Highlights
May 4, 2011
EAU 2011 - Evaluation of different molecular markers for the detection of minimal residual disease in lymph nodes of patients undergoing radical prostatectomy and extended pelvic lymph node dissection (PLND) - Session Highlights
May 4, 2011
Small prostate size and high grade disease-biology or artifact? - Abstract
May 3, 2011
Inhibition of prostate cancer using RNA interference-directed knockdown of platelet-derived growth factor receptor - Abstract
May 3, 2011
A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer - Abstract
May 3, 2011
Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer - Abstract
May 3, 2011
Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: Evidence, rationale, and future directions - Abstract
May 3, 2011
Computer-aided analysis of transrectal ultrasound images of the prostate - Abstract
May 3, 2011
Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: Results of a prospective study in a clinical setting - Abstra
May 3, 2011
Pathological findings after radical prostatectomy in men eligible for active surveillance (French trial SURACAP): Is the misclassification rate acceptable? - Abstract
May 3, 2011
Editor's Commentary - Association of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study
May 3, 2011
EAU 2011 - Open radical prostatectomy (ORP) performed by low volume surgeons predisposes to higher rates of venous thrombosis (VT) and pulmonary embolism (PE) - Session Highlights
May 3, 2011
EAU 2011 - Influence of high dose low molecular weight heparin (LMWH) on blood transfusion and lymphocele rate in open radical prostatectomy - Session Highlights
May 3, 2011
EAU 2011 - Combining screening and chemoprevention of prostate cancer - Session Highlights
May 3, 2011
EAU 2011 - Results from the Gothenburg randomized prostate cancer screening trial - Session Highlights
May 3, 2011
The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers - Abstract
May 2, 2011
Page 1405 of 1436
Start
Prev
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free